Synthesis and antiproliferative activity in vitro of 1-phenyl-2-(4-aryl-1,3,4,5-tetrahydropyrido[2,3-b][1,4]diazepin-2-ylidene) ethanone. Part I.

Polish Journal of Chemistry

Volumn 76, Issue 11, 2002, Pages 1607-1617

  Liszkiewicz, H ^a   Kowalska, M W ^a   Glowiak, T ^a   Wietrzyk, J ^a   Opolski, A ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

1 phenyl 2(aryl 1,3,4, 5 tetrahydropyrido 2,3 b 1,4 diazepin 2 ylidene) ethanone; 3 (2 amino pyridin 3 ylamino) 1 phenyl 2 buten 1 one; Crystal structure; Cytotoxicity

Indexed keywords

1 PHENYL 2 (3 HYDROXYPHENYL 1,3,4,5 TETRAHYDROPYRIDO[2,3 B][1,4]DIAZEPIN 2 YLIDENE)ETHANONE; 1 PHENYL 2 (4 PHENYL 1,3,4,5 TETRAHYDROPYRIDO[2,3 B][1,4]DIAZEPIN 2 YLIDENE)ETHANONE; 1 PHENYL 2 [2 (4 DIETHYLAMINOPHENYL 1,3,4,5 TETRAHYDROPYRIDO[2,3 B][1,4]DIAZEPIN 2 YLIDENE]ETHANONE; 1 PHENYL 2 [4 (3 METHYL 4 METHOXYPHENYL) 1,3,4,5 TETRAHYDROPYRIDO[2,3 B][1,4]DIAZEPIN 2 YLIDENE]ETHANONE; 1 PHENYL 2 [4 (3,4 DIMETHOXYPHENYL) 1,3,4,5 TETRAHYDROPYRIDO[2,3 B][1,4]DIAZEPIN 2 YLIDENE]ETHANONE; 1 PHENYL 2 [4 (3,4,5 TRIMETHOXYPHENYL) 1,3,4,5 TETRAHYDROPYRIDO[2,3 B][1,4]DIAZEPIN 2 YLIDENE]ETHANONE; 1 PHENYL 2 [4 (4 METHOXYPHENYL) 1,3,4,5 TETRAHYDROPYRIDO[2,3 B][1,4]DIAZEPIN 2 YLIDENE]ETHANONE; 2 METHYL 4 PHENYL 3H PYRIDO[2,3 B]DIAZEPINE; 2,3 DIAMINOPYRIDINE; 3 (2 AMINOPYRIDIN 3 YLAMINO) 1 PHENYL 2 BUTEN 1 ONE; ACETIC ACID; ACETONE; BENZALDEHYDE; BENZALDEHYDE DERIVATIVE; BENZOYLACETONE; DIAZEPINE DERIVATIVE; METHANOL; POTASSIUM HYDROXIDE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CATALYST; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; INFRARED RADIATION; PROTON NUCLEAR MAGNETIC RESONANCE; X RAY DIFFRACTION;

EID: 0036852184     PISSN: 01375083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Littell R. and Allen D.S., J. Med. Chem., 8, 722 (1965).
2. Fiakpui C.Y., Arora V.K. and Knaus E.E., J. Heterocycl. Chem. I, 30, 699 (1993).
3. Fiakpui C.Y., Phillips O.A., Murthy K.S.K. and Knaus E.E., J. Heterocycl. Chem., 36, 377 (1999).
4. Grozinger K.G., Byrne D.P., Nummy L.J., Ridges M.D. and Salvagno A., J. Heterocycl. Chem., 37, 229 (2000).
5. Eberlein W.G., Engel W.W., Trummlitz G., Schmidt G. and Hammer R., J. Med. Chem., 31, 1169 (1988).
6. Watanabe T., Kakefuda A., Tanaka A., Takizawa K., Hirano S., Shibata H., Yamagiwa Y. and Yanagisawa I., Chem. Pharm. Bull., 46, 53 (1998).
7. Karton T., Bradbury B.J., Baumgold J., Paek R. and Jacobson K.A., J. Med. Chem., 24, 2133 (1991).
8. Savelli F., Boido A. and Mulé A., Bull. Chim. Farmaceutico - Anno 128, 4, 132 (1989).
9. Nawrocka W., Sztuba B., Opolski A, Wietrzyk J., Kowalska M.W. and Głowiak T., Arch. Pharm. Pharm. Med. Chem., 334, 1 (2001).
10. Nawrocka W., Sztuba B. and Zimecki M., Arch. Pharm. Pharm. Med. Chem., 334, 11 (2001).
11. Blache Y., Hichour M., Di Blasi G., Chezal J.M., Viols H., Chavignon O., Teulade J.C. and Chapat J.P., Heterocycles, 51, 1003 (1999).
12. Halford J.C. and Fitsch R.M., J. Am. Chem. Soc., 85, 3354 (1963).
13. Staab H.A. and Vögtle F., Chem. Ber., 98, 2701 (1963).
14. Mannschreck A., Rissmann G., Vögtle F. and Wild D., Chem. Ber., 100, 335 (1967).
15. Nawojski A. and Nawrocka W., Roczn. Chem., 48, 1073 (1974).
16. Nawojski A., Prace Naukowe Akademii Medycznej we Wrocławiu, Rozprawa Habilitacyjna, Akademia Medyczna, Wrocław, 5(10) (1969).
17. Low J.N., Cobo J., Insuasty B., Insuasty H., Nogueras M. and Sanchez A., Acta Cryst., C58, 103 (2002).
18. Abramenko B.L., Sergienko V.S., Gamovskii A.D. and Porai-Kochitz M.A., Zh. Obsch. Khim., 60, 1593 (1990).
19. Rodier N., Agafonov V., Dubois P., Mariand M. and Cense J.M., Acta Cryst., C49, 156 (1993).
20. Dupont L., Liégeois I.F., Rogister F. and Delagre J., Acta Cryst., C52, 391 (1996).
21. Geran R.I., Greenberg N.H., MacDonald M.M., Schumacher A.M. and Abbott B.J., Cancer Chemotherapy Rep., 3, 59 (1972).
22. Sheldrick G.M., SHELXS97, Program for Solution of Crystal Structures, University of Göttingen (1997).
23. Sheldrick G.M., SHELXL97, Program for Crystal Structure Refinement, University of Göttingen (1997).
24. Sheldrick G.M., SHELXTL-NT V5.1, Bruker AXS (1999).
25. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S. and Boyol M.R., J. Natl. Cancer. Inst., 82, 1107 (1990).
26. Opolski A., Kuduk-Jaworka J., Wietrzyk J., Wojdat E., Waszkiewicz K., Romaniewska A., Radzikowski C., Anticancer Drugs, 11, 363 (2000).